Medicine

Audio Journal of Medicine: Maraviroc for HIV: Responses at 48 Weeks

Jacob Lalezari
Jacob Lalezari

REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.

Similar Interviews

  • Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety
  • HOWARD MAYER, Pfizer Global Research, New London CT MARK WAINBERG, McGill University, Montreal Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and

  • Human Growth Hormone: Responses in Severe Heart Failure
  • Catherine Demers Recombinent human growth hormone has achieved clinical responses when used for treating heart failure. Catherine Demers of McMaster University

  • Vaginal Progesterone Reduced Risk of Preterm Birth in Women with Short Cervix
  • Kypros Nicolaides REFERENCE: N Engl J Med 2007; 357: 426-9 KYPROS NICOLAIDES, Kings College Hospital, London The
    1. [...] 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him …Original post by admin delivered by Medtrials and [...]

      Posted by   Audio Journal of Medicine Maraviroc for HIV: Responses at 48 Weeks by medTRIALS.info | September 20, 2007, 12:03 pm

    Post a comment

    Subscribe to Audio Medica Podcast